This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.
Study Type
OBSERVATIONAL
Enrollment
446
Patients in CAPD who have received Fosrenol for hyperphosphatemia
Unnamed facility
Multiple Locations, Japan
Incidence of adverse drug reactions in subjects who received Fosrenol
Time frame: After Fosrenol administration, up to 1 year
Incidence of serious adverse events in subjects who received Fosrenol
Time frame: After Fosrenol administration, up to 1 year
Incidence of adverse drug reactions in subpopulation with baseline data [such as demographic data, concomitant disease, duration of treatment, maximum daily dose] and dose of Fosrenol
Time frame: After Fosrenol administration, up to 1 year
Effectiveness evaluation assessment [achievement rate of a goal phosphate level; 3.5-6 mg/dL]
Time frame: After Fosrenol administration, up to 1 year
Effectiveness evaluation assessment [achievement rate of a goal calcium level; 8.4-10.0 mg/dL]
Time frame: After Fosrenol administration, up to 1 year
Clinical test value collections [calciotropic hormones, bone turnover markers]
Time frame: After Fosrenol administration, up to 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.